These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 2396133)

  • 41. [Basis for the administration of streptomycin and isoniazid in ultrasonic aerosols in the treatment of intrathoracic tuberculosis].
    Semenova EV
    Antibiotiki; 1977 May; 22(5):469-71. PubMed ID: 879731
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
    Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Antituberculosis chemotherapy including ofloxacin in patients with pulmonary tuberculosis not treated previously].
    Tsukamura M; Yoshii S; Yasuda Y; Saito H
    Kekkaku; 1986 Jan; 61(1):15-7. PubMed ID: 3458966
    [No Abstract]   [Full Text] [Related]  

  • 44. Two excellent management tools for national tuberculosis programmes: history of prior treatment and sputum status at two months.
    Trébucq A; Rieder HL
    Int J Tuberc Lung Dis; 1998 Mar; 2(3):184-6. PubMed ID: 9526189
    [No Abstract]   [Full Text] [Related]  

  • 45. [Intravenous chemotherapy of pulmonary tuberculosis].
    Ivaniuta OM
    Vrach Delo; 1971 Jan; (1):84-7. PubMed ID: 4325153
    [No Abstract]   [Full Text] [Related]  

  • 46. [Our experience in short-course treatment of tuberculosis. Results obtained by using therapeutic regimens of 6 to 8 months].
    Ben Kheder A; Chabbou A; Zakhama B; Zaimi M; el Gharbi T; el Mekki L; el Gharbi B
    Bull Int Union Tuberc; 1985; 60(1-2):26-8. PubMed ID: 4074968
    [No Abstract]   [Full Text] [Related]  

  • 47. [Comparison of a 6-month chemotherapy and a l2-month chemotherapy in the treatment of pulmonary tuberculosis in Algerian Sahara. Cooperative study by an Algerian work team and the British Medical Research Council].
    Chaulet P
    Bull Int Union Tuberc; 1985; 60(1-2):31-3. PubMed ID: 4074970
    [No Abstract]   [Full Text] [Related]  

  • 48. [Tarivid in the combination therapy of patients with pulmonary tuberculosis].
    Koriakin VA; Zeliger LR; Galenko NN
    Probl Tuberk; 1991; (9):38-40. PubMed ID: 1749755
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Four drug combination including Ethambutol and early switching to entirely new regimen in initial treatment of pulmonary tuberculosis].
    Kekkaku; 1970 Jul; 45(7):219-26. PubMed ID: 5449509
    [No Abstract]   [Full Text] [Related]  

  • 50. [The short-term and long-term treatment outcomes in patients with pulmonary tuberculosis positive for drug-resistant and sensitive strains].
    Han JP; Sun SL; Li RZ; Zhang FS; Wang SC; Cheng J; Deng YF; Wang Y; Yu CB
    Zhonghua Jie He He Hu Xi Za Zhi; 2003 Feb; 26(2):70-3. PubMed ID: 12783654
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
    Kekkaku; 1980 Jan; 55(1):7-13. PubMed ID: 6988627
    [No Abstract]   [Full Text] [Related]  

  • 52. [Intermittent 2-phase therapy using ethambutol-INH-streptomycin].
    Eule H; Fichtner K; Gross V; Sellau J
    Z Erkr Atmungsorgane Folia Bronchol; 1972 Apr; 136(2):139-57. PubMed ID: 4627225
    [No Abstract]   [Full Text] [Related]  

  • 53. [Classification of destructive pulmonary tuberculosis into groups according to quantitative and qualitative characteristics with the aim of developing differentiated treatment methods].
    Smirnov GA; Valiev RSh
    Probl Tuberk; 1999; (5):11-4. PubMed ID: 10565207
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [A controlled trial of 6-month and 12-month regimens after negative conversion of sputum in the original treatment of pulmonary tuberculosis. Report of the 21st series of controlled trials of chemotherapy. Cooperative Study Unit of Chemotherapy of Tuberculosis of National Sanatoria in Japan (CSUCTNS)].
    Kekkaku; 1984 Feb; 59(2):81-9. PubMed ID: 6379258
    [No Abstract]   [Full Text] [Related]  

  • 55. Short-course intensive treatment of patients with destructive pulmonary tuberculosis.
    Bondarev IM
    Scand J Respir Dis Suppl; 1978; 102():53-5. PubMed ID: 278216
    [No Abstract]   [Full Text] [Related]  

  • 56. [Local treatment of tuberculosis by the intrapulmonary administration of antibacterial drugs].
    Litvinov AA; Usatiuk AI
    Vrach Delo; 1981 May; (5):27-8. PubMed ID: 7257256
    [No Abstract]   [Full Text] [Related]  

  • 57. [Differential pathogenetic therapy in the complex treatment of patients with destructive pulmonary tuberculosis].
    Molotkov VN; Ivaniuta OM; Bystritskaia VI; Mel'nik VN
    Probl Tuberk; 1982 Feb; (2):45-8. PubMed ID: 7063479
    [No Abstract]   [Full Text] [Related]  

  • 58. [Late results of treating destructive pulmonary tuberculosis by using the endobronchial drop administration of antitubercular preparations].
    Patrikeev GA; Kolesov IuI; Karaduta VK
    Probl Tuberk; 1979 Oct; (10):21-4. PubMed ID: 504103
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparative studies of various antituberculosis drug regimens by means of serum antimycobacterial activity tests in man.
    Hokama S
    Jpn J Tuberc; 1967 Jul; 14(1):55-65. PubMed ID: 5300098
    [No Abstract]   [Full Text] [Related]  

  • 60. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.